A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial

详细信息    查看全文

• 作者：Jan C. Drooger ; Harm van Tinteren ; Steffen M. de Groot ; Albert J. ten Tije ; Hiltje de Graaf ; Johanneke E. A. Portielje ; Agnes Jager ; Aafke Honkoop ; Sabine C. Linn ; Judith R. Kroep ; Frans L. G. Erdkamp ; Paul Hamberg ; Alex L. T. Imholz ; Quirine C. van Rossum-Schornagel ; Joan B. Heijns ; A. Elise van Leeuwen-Stok and Stefan Sleijfer
• 刊名：Cancer
• 出版年：2016
• 出版时间：October 1, 2016
• 年：2016
• 卷：122
• 期：19
• 页码：2961-2970
• 全文大小：291K
• ISSN：1097-0142

文摘

To explore the role of bevacizumab and a chemotherapy-free approach, the authors evaluated the combination of bevacizumab, trastuzumab, and paclitaxel (HAT) and the regimen of trastuzumab and bevacizumab (HA) with the addition of paclitaxel after progression (HA-HAT) as first-line treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.